Correlation of Serum Magnesium and Blood Lipid Profile in Under-Peritoneal Dialysis and Hemodialysis Patients

Document Type : مقاله کوتاه

Authors

1 Associate Professor, Department of Nephrology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

2 Resident, Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

3 Professor, Department of Nephrology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Lipid abnormalities, is one of the major causes of cardiovascular diseases in under-dialysis patients. This study aimed to assess the relationship of serum magnesium and blood lipid profile in patients under the peritoneal dialysis and hemodialysis.Methods: This cross- sectional study was performed on 110 under-dialysis patients in Zahedan, Iran. Serum lipids and magnesium levels were measured. Data were analyzed using t and Pearson correlation tests.Findings: The mean age of the patients was 46.1 ± 14.7 years. In under-peritoneal dialysis patients, who were not under the treatment of antilipid agents, the correlation of serum magnesium with triglyceride and very low-density lipoprotein cholesterol (VLDL) was significant (P < 0.05); whereas the correlation of serum magnesium with cholesterol and low-density lipoprotein cholesterol (LDL-C) was significant only in subgroup who were under treatment of antilipid agents (P < 0.05). In under-hemodialysis group, the correlation of serum magnesium with cholesterol, triglyceride and  was significant (P < 0.05).Conclusion: This study showed that serum magnesium had correlation with serum lipid profile and could contribute to atherosclerosis and cardiovascular diseases in the patients under the peritoneal dialysis and hemodialysis.

Keywords

References

  1. Kazemeini SM, Nafar M, Aghighi M, Heidari A .The status of renal replacement therapy in Iran. Hakim Res J 2003; 6(1): 7-12. [In Persian].
  2. Nasri H. Elevated serum parathyroid hormone is a heart risk factor in hemodialysis patients. J Parathyroid Dis 2013; 1(1): 13-4.
  3. Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Impact of vitamin D on the immune system in kidney disease. J Parathyroid Dis 2013; 1(2): 17-20.
  4. Amiri M, Nasri H. Secondary Hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyroid Dis 2014; 2(1): 1-2.
  5. Nasri H, Baradaran A. The influence of serum 25-hydroxy vitamin D levels on Helicobacter Pylori Infections in patients with end-stage renal failure on regular hemodialysis. Saudi J Kidney Dis Transpl 2007; 18(2): 215-9.
  6. Hajivandi A, Amiri M. World Kidney Day 2014: Kidney disease and elderly. J Parathyroid Dis 2014; 2(1):3-4.
  7. Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med Sci 2014; 19(4): 358-67.
  8. Rafieian-Kopaie M, Nasri H. Platelet counts and mean platelet volume in association with serum magnesium in maintenance hemodialysis patients. J Ren Inj Prev 2012; 1(1): 17-21.
  9. Nasri H. Correlation of serum magnesium with serum levels of 25-hydroxyvitamin D in hemodialysis patients. J Parathyroid Dis 2014; 2(1): 11-3.
  10. Nasri H, Kheiri S. Effects of diabetes mellitus, age, and duration of dialysis on parathormone in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2008; 19(4): 608-13.
  11. Baradaran A. Primary hyperparathyroidism and kidney; recent findings. J Parathyroid Dis 2014; 2(1): 5-6.
  12. Nasri H. The awareness of chronic kidney disease and aging; the focus of world kidney day in 2014. J Nephropharmacol.2014; 3(1): 1-2.
  13. Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997; 20(5): 426-32.
  14. Nasri H. Association of serum lipoprotein (a) with hypertension in diabetic patients. Saudi J Kidney Dis Transpl 2008; 19(3): 420-7.
  15. Amiri M, Nasri H. Secondary hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyroid Dis 2014; 2(1): 1-2.
  16. Nissenson AR, Prichard SS, Cheng IK, Gokal R, Kubota M, Maiorca R, et al. Non-medical factors that impact on ESRD modality selection. Kidney Int Suppl 1993; 40: S120-S127.
  17. Nasri H. Impact of diabetes mellitus on parathyroid hormone in hemodialysis patients. J. Parathyr Dis 2013; 1(1): 9-11.
  18. Ghorbani A, Baradaran A.Magnesium and diabetes mellitus. J Ren Inj Prev 2012; 1(2): 46-7.
  19. Baradaran A. Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues. J Nephropathol 2012; 1(3): 126-9.
  20. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34(6): 1065-74.
  21. Nasri H. Serum leptin concentration and left ventricular hypertrophy and function in maintenance hemodialysis patients. Minerva Urol Nefrol 2006; 58(2): 189-93.
  22. Rafieian-Kopaei M, Nasri H. Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients. J Ren Inj Prev 2013; 2(2): 47-50.
  23. van der Hel WS, van den Bergh WM, Nicolay K, Tulleken KA, Dijkhuizen RM. Suppression of cortical spreading depressions after magnesium treatment in the rat. Neuroreport 1998; 9(10): 2179-82.
  24. Mubarak M, Nasri H. Antiphospholipid antibodies and systemic scleroderma. Turk J Haematol 2013; 30(4): 429-30.
  25. Nasri H. Association of Ca×PO4 product with levels of serum C-reactive protein in regular hemodialysis patients. J Ren Inj Prev 2012; 1(2): 55-9.
  26. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136(3): 480-90.
  27. Nasri H, Rafieian-Kopaei M. Significant difference of serum 25-hydroxyvitamin D level in male hemodialysis patients with our without diabetes; a single center study. J Nephropharmacol 2012;1(2):15-6.
  28. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995; 48(7): 927-40.
  29. Nasri H. Helicobacter pylori infection and its relationship to plasma magnesium in hemodialysis patients. Bratisl Lek Listy 2007; 108(12): 506-9.
  30. Laurant P, Hayoz D, Brunner H, Berthelot A. Dietary magnesium intake can affect mechanical properties of rat carotid artery. Br J Nutr 2000; 84(5): 757-64.
  31. Mountokalakis TD. Magnesium metabolism in chronic renal failure. Magnes Res 1990; 3(2): 121-7.
  32. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86(2): 475-82.
  33. Baradaran A. Beyond mineral metabolism, the bright immunomodulatory effect of vitamin D in renal disease. J Nephropharmacol 2012; 1(2):17-8.
  34. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27(1): 84-91.
  35. Nasri H, Baradaran A. Association of serum lipoprotein(a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. Transplant Proc 2004; 36(9): 2683-6.
  36. Rouhi H, Ganji F. Effects of N-acetyl cysteine on serum lipoprotein (a) and proteinuriain type 2 diabetic patients. J Nephropathol 2013; 2(1): 61-6.
  37. Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. Acta Medica (Hradec Kralove) 2004; 47(4): 263-5.
  38. Robles NR, Escola JM, Albarran L, Espada R. Correlation of serum magnesium and serum lipid levels in hemodialysis patients. Nephron 1998; 78(1): 118-9.
  39. Ansari MR, Maheshwari N, Shaikh MA, Laghari MS, Lal K, Ahmed K. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl 2012; 23(1): 21-5.
  40. Fytili CI, Progia EG, Panagoutsos SA, Thodis ED, Passadakis PS, Sombolos KI, et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2002; 24(5): 623-30.
  41. Tamadon MR. Secondary hyperparathyroidism and chronic kidney disease. J Parathyroid Dis.2013; 1(1):15-6.
  42. Kimak E, Berger B, Solski J, Janicka L, Ksiazek A. Comparison of lipid and lipoprotein profiles in long-term chronic ambulatory peritoneal dialysis (CAPD) in elderly patients with chronic renal failure (CRF). Int Urol Nephrol 2002; 33(1): 203-4.
  43. Nasri H. Elevated serum parathyroid hormone is a heart risk factor in hemodialysis patients. J Parathyr Dis 2013; 1(1):13-4.
  44. Nasri H, Rafieian-Kopaei M. Serum anti-hepatitis B surface antigen in hemodialysis patients. J Nephropharmacol. 2012; 1(1):3-5.
  45. Ong-Ajyooth L, Sirisalee K, Shayakul C, Vareesangthip K, Vasuvattakul S, Vanichakarn S, et al. Comparison of lipid abnormalities in continuous ambulatory peritoneal dialysis and hemodialysis patients. Transplant Proc 1994; 26(4): 2077-9.
  46. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidemia and progressive renal disease. Kidney Int Suppl 1991; 31: S41-S48.
  47. Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998; 13(Suppl 1): 45-9.
  48. de Gomez Dumm NT, Giammona AM, Touceda LA, Raimondi C. Lipid abnormalities in chronic renal failure patients undergoing hemodialysis. Medicina (B Aires) 2001; 61(2): 142-6.
  49. Baradaran A, Behradmanesh S, Nasri H. Association of body mass index and serum vitamin D level in healthy Iranian adolescents. Endokrynol Pol 2012; 63(1): 29-33.
Journal of Isfahan Medical School
Volume 32, Issue 291 - Serial Number 291
May and June 2014
Pages 1010-1017

Files

History

  • Receive Date: 12 March 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics